CCKBR and neoplasm: Treatment with the mTORC1 inhibitor RAD001 (everolimus) also bears the potential to enhance CCK2R overexpression leading to improved tumor uptake of [177Lu]Lu-PP-F11N in A431-CCK2R xenografts (~20% IA/g), while simultaneously maintaining the uptake in other CCK2R-expressing organs unchanged [33].